Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 16,51 € (+84,68 %). La mediana es de 16,81 € (+88,03 %).
| Comprar |
29 |
| Mantener |
7 |
| Vender |
3 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
ARK Invest expands position in Intellia Therapeutics and reduces Brera holding
ARK Invest increased its position in Intellia Therapeutics by 89,284 shares worth about 1.09 million USD via the ETFs ARKK and ARKG. At the same time, ARK sold 4,156 shares of Brera Holdings for approximately 15,377 USD through ARKK, ARKW and ARKF. ARK also bought shares of the 3iQ Solana Staking ETF (4,021 shares, about 33,615 USD), reflecting a strategic focus on biotechnology and selective investments in crypto assets. » Más en de.investing.com
Intellia Therapeutics receives FDA priority review for lonvo-z, stock rises
The FDA has formally accepted the Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) and granted a priority review; the PDUFA date is March 10, 2027. A decision by an advisory committee is not currently planned, reducing regulatory uncertainty. The filing is based on strong Phase 3 data from the HAELO study showing a median reduction in monthly HAE attacks of 87% and 62% of patients attack-free over six months. Analysts reaffirmed a "Market Outperform" rating with a $30.00 price target, creating a near-term catalyst for the stock. » Más en de.investing.com
ARK increases stake in Intellia Therapeutics and reduces Brera positions
Cathie Wood’s ARK bought 39,548 shares of Intellia Therapeutics on September 3 via the ARKG ETF for about $504,632, continuing a series of increases started in the days before. At the same time, ARK sold a total of 10,853 shares of Brera Holdings across several ETFs for roughly $41,241, further trimming the position in recent days. The transactions reflect a strategic reallocation in favor of Intellia and a reduction of exposure to Brera. » Más en de.investing.com
Intellia shows strong phase‑3 data for CRISPR gene therapy lonvo‑z against hereditary angioedema
Intellia presented phase‑3 data from the HAELO study showing lonvo‑z reduced the monthly rate of attacks requiring treatment between weeks 5 and 28 by 89% versus placebo (0.19 vs. 1.79). Moderate to severe attacks fell by 91% and quality of life improved substantially more than with placebo. Adverse events were mostly mild to moderate, and no serious events were reported in the treatment arm. Intellia has filed a rolling BLA with the FDA and expects approval and a U.S. launch in the first half of 2027, while the stock has recently fallen despite the data. » Más en de.investing.com
Intellia share price falls after $180 million capital raise at steep discount
The Intellia share dropped more than 8% in premarket trading to $12.09 after the company placed roughly 16.7 million shares at $10.75 each. The offering was increased from an initial $150 million to $180 million and was conducted at an 18.6% discount to the closing price. Proceeds are intended to finance clinical development, the commercialization of lead programs, R&D of additional candidates, and potential acquisitions. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 6,32 M | 46,15 % |
| Beneficio bruto | 6,32 M | 111,39 % |
| Beneficio neto | -112,55 M | 30,36 % |
| EBITDA | -112,01 M | 36,37 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1236,91 M € |
Número de acciones | 140,36 M |
Máximo/mínimo de 52 semanas | 16,79 € - 7,22 € |
| Dividendos | No |
Beta | 1,82 |
Ratio P/E | -2,90 |
Ratio PEG | -0,12 |
Ratio P/B | 2,22 |
Ratio P/S | 25,74 |
Perfil de la empresa
Intellia Therapeutics, Inc., una empresa de edición genómica, se centra en el desarrollo de terapias. Los programas in vivo de la compañía incluyen NTLA-2001, que se encuentra en ensayo clínico de Fase 1 para el tratamiento de la amiloidosis por transtiretina; y NTLA-2002 para el tratamiento del angioedema hereditario, así como otros programas centrados en el hígado que abarcan la hemofilia A y la hemofilia B, la hiperoxaluria tipo 1 y el déficit de alfa-1 antitripsina. Su pipeline ex vivo incluye NTLA-5001 para el tratamiento de la leucemia mieloide aguda; y programas propios centrados en el desarrollo de terapias celulares modificadas para tratar diversos trastornos oncológicos y autoinmunes. Además, ofrece herramientas que comprenden el sistema Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9). Intellia Therapeutics, Inc. tiene acuerdos de licencia y colaboración con Novartis Institutes for BioMedical Research, Inc. para modificar células madre hematopoyéticas para el tratamiento de la anemia falciforme; con Regeneron Pharmaceuticals, Inc. para codesarrollar posibles productos para el tratamiento de la hemofilia A y la hemofilia B; con Ospedale San Raffaele; y una colaboración estratégica con SparingVision SAS para desarrollar nuevos medicamentos genómicos que utilizan la tecnología CRISPR/Cas9 para el tratamiento de enfermedades oculares. La compañía se conocía anteriormente como AZRN, Inc. Intellia Therapeutics, Inc. se constituyó en 2014 y tiene su sede en Cambridge, Massachusetts.
| Nombre | Intellia Therapeutics |
| CEO | John Leonard |
| Sede | Cambridge,
ma Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Herramientas y servicios de ciencias de la vida |
| Salida a bolsa | 06/05/2016 |
| Empleados | 377 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | NTLA |
London Stock Exchange | 0JBU.L |
Frankfurt | 38I.F |
Düsseldorf | 38I.DU |
London | 0JBU.L |
SIX | 38I.SW |
München | 38I.MU |